Literature DB >> 17264582

Miliary tuberculosis in Qatar: a review of 32 adult cases.

H Alsoub1, F S Al Alousi.   

Abstract

BACKGROUND: This study was conducted to define the demographic, clinical and laboratory features, methods of diagnosis and outcome, in patients with miliary tuberculosis (TB) in Qatar, and compare the findings with other reported studies. PATIENTS AND METHODS: A retrospective review of 32 cases of miliary TB treated at the Hamad Medical Corporation during a seven-year period (1992 to 1998) was undertaken. The 32 patients comprised 24 males and 8 females, and their mean age was 33.3 years. The majority (90%) were expatriates. The clinical features of the patients were similar to those of previously reported series. The most common presenting symptoms were fever, cough, night sweats, weight loss and sputum production. Fever, rales, lymphadenopathy, altered mental status and hepatomegaly were the most common signs. Chest radiograph was abnormal in 94% of patients, and showed a miliary pattern in 69%. Sputum, cerebrospinal fluid, bronchial washings, and urine smears for acid-fast bacilli were rarely positive, however, cultures for Mycobacterium tuberculosis were positive in 54.8%, 37.5%, 33%, and 25%, respectively. The diagnoses in the majority of patients were made on the basis of the clinical presentation and supported by a miliary pattern on chest radiograph. In those whom chest radiograph did not show the classic miliary pattern, transbronchial biopsy was diagnostic in 1 of 2 patients (50%), bone marrow biopsy in 5 of 11 (45%), liver biopsy in 1 of 2 (50%), and lymph node biopsy in all 7 patients (100%). Thirty patients were treated with a four-drug regimen consisting of isoniazid, rifampin, pyrazinamide, and streptomycin or ethambutol. Mortality due to miliary TB was 3%.
CONCLUSION: Miliary TB is common in Qatar, especially among expatriates. Because the clinical features of the disease are nonspecific, a high index of suspicion is essential for early diagnosis in order avoid delays in therapy and poor outcome.

Entities:  

Year:  2001        PMID: 17264582     DOI: 10.5144/0256-4947.2001.16

Source DB:  PubMed          Journal:  Ann Saudi Med        ISSN: 0256-4947            Impact factor:   1.526


  7 in total

1.  Metastatic cancer masquerading as miliary tuberculosis in an immunocompetent young adult.

Authors:  Peng Yun Ng; Mustafa Kadam; Craig Batista
Journal:  BMJ Case Rep       Date:  2022-05-24

Review 2.  Challenges in the diagnosis & treatment of miliary tuberculosis.

Authors:  Surendra K Sharma; Alladi Mohan; Abhishek Sharma
Journal:  Indian J Med Res       Date:  2012-05       Impact factor: 2.375

Review 3.  Miliary tuberculosis: A new look at an old foe.

Authors:  Surendra K Sharma; Alladi Mohan; Animesh Sharma
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2016-03-18

4.  Role of Fiberoptic Bronchoscopy in the Rapid Diagnosis of Sputum Smear-negative Disseminated Tuberculosis with Pulmonary Miliary Infiltrates.

Authors:  Fahmi Yousef Khan; Aisha Hussein Aladab
Journal:  Oman Med J       Date:  2020-01-15

5.  Comparison of clinical manifestations and treatment outcome according to age groups in adult patients with miliary tuberculosis.

Authors:  Jaehee Lee; Jae Kwang Lim; Eun Jin Kim; Deok Heon Lee; Yu Kyung Kim; Seung Soo Yoo; Shin Yup Lee; Seung Ick Cha; Jae Yong Park; Chang Ho Kim
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

6.  Rodent-Related Zoonotic Pathogens at the Human-Animal-Environment Interface in Qatar: A Systematic Review and Meta-Analysis.

Authors:  Md Mazharul Islam; Elmoubashar Farag; Ahmad Mahmoudi; Mohammad Mahmudul Hassan; Ehsan Mostafavi; Khalid A Enan; Hamad Al-Romaihi; Muzzamil Atta; Abdel Rahim M El Hussein; Zilungile Mkhize-Kwitshana
Journal:  Int J Environ Res Public Health       Date:  2021-05-31       Impact factor: 3.390

Review 7.  Clinical review: tuberculosis on the intensive care unit.

Authors:  Guy Hagan; Nazim Nathani
Journal:  Crit Care       Date:  2013-09-27       Impact factor: 9.097

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.